Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
09:55am, Friday, 21'st Apr 2023
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
The Greatest 7 Blue-Chip Stocks to Buy for Your Portfolio
01:07pm, Thursday, 20'th Apr 2023
While the debate will certainly rage over which ideas legitimately rank as the greatest blue-chip stocks to buy of all time, for right now, certain enterprises stand out for a combination of their rel
Regeneron: New Highs Following Dupixent's COPD Data
06:12am, Thursday, 13'th Apr 2023
Shares of Regeneron jumped to new all-time highs following the successful phase 3 results of Dupixent in COPD. COPD could be a $3 billion or greater a year opportunity for Dupixent and should push its
Regeneron Announces Investor Conference Presentations
04:00pm, Tuesday, 11'th Apr 2023
TARRYTOWN, N.Y., April 11, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
Investing $1,000 In These 2 Top Stocks Would Be a Great Move
09:30am, Sunday, 09'th Apr 2023
HCA Healthcare will recover from pandemic-related troubles given enough time. Regeneron's recent clinical and regulatory developments should improve its prospects.
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?
01:44pm, Friday, 07'th Apr 2023
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
2 Top Growth Stocks That Could Soar This Spring
05:39am, Thursday, 06'th Apr 2023
An experimental new gene therapy from Sarepta Therapeutics has an upcoming date with the Food and Drug Administration and a panel of independent experts. An approval decision coming in June could exte
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:55am, Tuesday, 04'th Apr 2023
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023
04:00pm, Monday, 03'rd Apr 2023
TARRYTOWN, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2023 financial and operating results on Thursda
Xeris Biopharma announces research evaluation collaboration and option agreement with Regeneron for XeriJect
11:31am, Thursday, 30'th Mar 2023
Xeris Biopharma Holdings (NASDAQ:XERS) told investors it has entered into a platform research evaluation collaboration and option agreement with Regeneron Pharmaceuticals Inc. Under the terms of the a
Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?
05:48am, Thursday, 30'th Mar 2023
Dupixent's recent clinical data suggest it is a viable treatment option for adult patients with chronic obstructive pulmonary disease (COPD). The medicine could top $3 billion in annual revenue for Sa
Final Trades: Regeneron, Hess & Bank of America
02:25pm, Monday, 27'th Mar 2023
The "Halftime Report" traders give their top picks to watch for the second half.
Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
01:26pm, Monday, 27'th Mar 2023
Shares of Sanofi (NASDAQ: SNY) were up 10.20% the week ended March 24, while Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) finished with a gain of 9.68%, following promising news about the companies'
Regeneron, Sanofi Look for Billions From COPD Drug
10:00am, Saturday, 25'th Mar 2023
The companies said Dupixent showed positive results in a late-stage study of current or former smokers with the killer disease.
Stock Trading Action Plan: Can The Market Bootstrap Itself To A Strong March Finish?
05:10pm, Friday, 24'th Mar 2023
The Nasdaq defended gains, plus its budding rally attempt, as stock trading heads into what could be a strong final week of March. The post Stock Trading Action Plan: Can The Market Bootstrap Itself T
